Degarelix

證據等級: L5

預測適應症: 10 個

Degarelix: From Advanced Prostate Cancer to Hypertrichosis

One-Sentence Summary

Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist generally used in advanced, hormone-dependent prostate cancer. The TxGNN model predicts it may be effective for Hypertrichosis (disease), but this ranks as the top of a broader list of low-plausibility predictions, with 0 clinical trials and 0 publications currently supporting this specific indication.

Quick Overview

Item	Content
Original Indication	Advanced hormone-dependent prostate cancer (based on general drug class knowledge; not present in this evidence pack — see Data Gaps)
Predicted New Indication	Hypertrichosis (disease)
TxGNN Prediction Score	99.99%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on general known information, Degarelix is a GnRH receptor antagonist that suppresses luteinizing hormone and testosterone release, an effect well established in advanced prostate cancer.

The top-ranked predicted indication, hypertrichosis, is mechanistically linked only in a narrow subset of cases: some androgen-dependent hypertrichosis subtypes could theoretically respond to testosterone suppression. However, the majority of hypertrichosis presentations (including the congenital and hair-shaft-structural subtypes also predicted at lower ranks) are not androgen-driven and have no known relationship to the HPG axis.

No clinical trials, ICTRP registrations, or PubMed literature specific to degarelix and hypertrichosis were found. Notably, the 20 literature records retrieved under rank 4 ("malformation syndrome with odontal/periodontal component") were reviewed and found to concern periodontitis pathology and treatment generally — they do not mention degarelix or GnRH antagonists and appear to be a keyword-matching artifact rather than genuine supporting evidence. This prediction should be treated as a model-score-only hypothesis (L5) pending mechanistic and clinical validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Degarelix is currently not marketed in Finland (0 marketing authorizations found in the queried registry).

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/Fimea package insert warnings and contraindications data could not be retrieved (Blocking data gap DG001) and are required before any S1 safety pre-assessment can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by TxGNN model score with no corroborating clinical trials or literature (Evidence Level L5), and the mechanistic rationale applies to only a narrow, androgen-dependent subset of hypertrichosis. A Blocking-severity gap in regulatory safety data (TFDA/Fimea package insert) also prevents any safety pre-assessment.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — Blocking gap DG001
Confirmed mechanism of action data from DrugBank — High-priority gap DG002
Targeted literature/clinical search specifically for "degarelix AND hypertrichosis" (current 20-record literature match under rank 4 is unrelated noise and should be excluded)
Preclinical or case-level evidence establishing a causal link between androgen suppression and the specific hypertrichosis subtype targeted
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.